Epilepsy

Preliminary results showed that a fusion of accelerometry and blood volume post modalities achieved the best AUC-ROC for 9 combined seizure types.

Aquestive does not anticipate a need for any additional studies and is preparing for the commercial launch of Libervant in the first half of 2022, if approved.

Here's what is coming soon to NeurologyLive.

Joseph Sullivan, MD, and Elaine C. Wirrell, discuss the transition of care into adulthood of patients with Dravet syndrome.

Key opinion leaders discuss managing patient expectations regarding clinical trials for Dravet syndrome treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 30, 2021.

Patients with neurological sequelae from COVID-19 were significantly more likely to die before discharge (22.2%) compared with non-neuro-COVID patients (14.4%).

Many applicants referenced an early interest and exposure to neurology, often describing their first courses in neurology sparking their desire to learn more about how the brain works.

Here's what is coming soon to NeurologyLive.

A discussion of new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.

The impact of new drug approvals on the consensus guidelines for the treatment of Dravet syndrome.

Investigators observed declines in delayed verbal recall in 20% to 30% of individuals who underwent a dominant temporal lobe resection for treatment of epilepsy.

Neurology News Network for the week ending July 24, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 23, 2021.

Basis for the approval was the SENZA-PDN randomized controlled trial, which showed the system’s ability to substantially sustain pain relief and improve health-related quality of life.

Treatment retention with cenobamate ranged from 73% of patients at 1 year to 59% of patients at 6 years.

The panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.  

The panel discusses future gene therapies in development for Dravet syndrome.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending July 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 15, 2021.

The FDA breakthrough device designation follows a pilot study where patients showed a 44% median reduction in seizures when treated with Neuroelectrics’ transcranial electrical stimulation platform.

Joseph Sullivan, MD, provides an overview of the recent approval of fenfluramine oral solution for the treatment of Dravet syndrome.

Elaine C. Wirrell, MD, provides an overview of cannabidiol oral solution for treatment of seizures associated with Dravet syndrome.

Here's what is coming soon to NeurologyLive.